|1.||Nicholas, John: 2 articles (08/2015 - 01/2014)|
|2.||Chen, Daming: 2 articles (08/2015 - 01/2014)|
|3.||Hu, Bo: 2 articles (06/2014 - 12/2011)|
|4.||Wang, Yibo: 2 articles (10/2010 - 03/2006)|
|5.||Zheng, Yi: 2 articles (10/2010 - 03/2006)|
|6.||Hui, Rutai: 2 articles (10/2010 - 03/2006)|
|7.||Pongrattanaman, Nunthapol: 1 article (06/2015)|
|8.||Wongwanit, Chumpol: 1 article (06/2015)|
|9.||Sritongsathian, Chukij: 1 article (06/2015)|
|10.||Praditsuktavorn, Banjerd: 1 article (06/2015)|
01/01/2014 - "This framework describes chemical properties of ARs, established macromolecular interactions by inhibition of vitamin K epoxide reductase, cellular responses including altered clotting factor processing and coagulopathy, organ level effects such as hemorrhage, organism responses with linkages to reduced fitness and mortality, and potential consequences to predator populations. "
11/01/2012 - "Genetic variants of vitamin K epoxide reductase (VKORC-1) are associated with increased VKA effect and bleeding risk. "
01/01/2013 - "Several studies have linked mutations in the genes encoding cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex 1 (VKORC1) to a reduced VKA dose requirement and an increased risk of bleeding. "
03/01/2014 - "However, as shown by fatal neonatal bleeding in mice that lack vitamin K epoxide reductase (VKOR), the low requirements are dependent on the ability of animals to regenerate vitamin K from its epoxide metabolite via the vitamin K cycle. "
05/01/2008 - "Combined vitamin K-dependent clotting factor (VKCF) deficiency type 2 (VKCFD2) is a rare bleeding disorder caused by mutated vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) gene. "
10/01/2008 - "Variation in the gene that encodes the vitamin K epoxide reductase subunit 1 (VKORC1) was recently proposed as a genetic risk factor for stroke in a Chinese population. "
11/01/2014 - "Warfarin, a vitamin K epoxide reductase inhibitor, is the oral anticoagulant most commonly used to reduce the risk of stroke in patients with atrial fibrillation (AF). "
01/01/2007 - "This study sought to determine the contribution of four genes, vitamin K epoxide reductase (VKORC1), gamma-glutamyl carboxylase (GGCX), calumenin (CALU), and cytochrome P450 2C9 (CYP2C9) to the warfarin maintenance dose required in Japanese patients following ischemic stroke. "
|4.||Hypoprothrombinemias (Prothrombin Deficiency)
09/01/1989 - "This confirms the hypothesis that NMTT-cephalosporins are inhibitors of hepatic vitamin K epoxide reductase, and that this is at least partly responsible for the clinically observed hypoprothrombinemia. "
10/15/1986 - "These data suggest that the hypoprothrombinemia which has been observed following use of these antibiotics results from the inactivation of the liver vitamin K epoxide reductase by NMTT or a NMTT metabolite."
08/15/1989 - "These results suggest that some antibiotics inhibit liver microsomal vitamin K epoxide reductase, which causes hypoprothrombinemia to develop under vitamin K-deficient conditions."
01/01/1988 - "The data suggest that NMTT-cephalosporins are inhibitors of hepatic vitamin K epoxide reductase and that a lower nutritional-vitamin K status predisposes to hypoprothrombinemia."
06/01/2014 - "The vitamin K epoxide reductase complex subunit 1 (VKORC1), the rate-limiting enzyme for vitamin K recycling, is significantly down-regulated in the kidneys of urolithiasis patients. "
07/01/2012 - "Re: Decreased expression of vitamin k epoxide reductase complex subunit 1 in kidney of patients with calcium oxalate urolithiasis."
12/01/2011 - "Decreased expression of vitamin K epoxide reductase complex subunit 1 in kidney of patients with calcium oxalate urolithiasis."
|1.||Cytochrome P-450 Enzyme System (Cytochrome P450)
|3.||glutamyl carboxylase (gamma-glutamyl carboxylase)
|5.||Proteins (Proteins, Gene)
|6.||Blood Coagulation Factors (Coagulation Factor)
|7.||Anti-Bacterial Agents (Antibiotics)
|8.||Cephalosporins (Cephalosporin Antibiotics)